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Abstract
Herpes simplex virus (HSV) has increasingly been associated with pulmonary disease in critically ill patients. However, the clinical rele-
vance of HSV is still a topic of debate. Monitoring of HSV in a quantitative way could potentially give relevant information on its role in
the pathogenesis of lower respiratory tract infection. A fast and reliable quantitative real-time PCR (Q-PCR) for the quantitative detec-
tion of HSV-1 and HSV-2 DNA was developed. A prospective observational study was performed in an intensive-care unit (ICU) to
monitor the HSV viral load in lower respiratory tract aspirates of long-term mechanically ventilated patients. HSV was common in the
lower respiratory tract (LRT) of critically ill patients with mechanical ventilation for at least 48 h (62%, n = 65/105). Detection of HSV
was signiﬁcantly associated with prolonged mechanical ventilation (p <0.01), prolonged ICU stay (p <0.01), and development of ventila-
tor-associated pneumonia (p ¼ 0.02). Corticosteroid administration (p <0.01) in the ICU and anti-HSV IgG seropositivity (p <0.01)
were risk factors for the occurrence of HSV in the LRT. The fact that no HSV-seronegative patient became positive suggests that all
HSV DNA-positive patients had HSV reactivations. Monitoring the HSV viral load in the LRT of critically ill patients showed a typical
homogeneous pattern of HSV kinetics. HSV emerged in tracheal and bronchial aspirates after a median of 7 days of intubation (5–
11 days), and this was followed by an exponential increase (c. 1 log copies/mL/day) to reach very high HSV peaks (106–1010 copies/mL)
in 78% of the HSV DNA-positive patients.
Keywords: Critically ill, herpes simplex virus, kinetics, lower respiratory tract, mechanical ventilation, monitoring, real-time PCR, venti-
lator-associated pneumonia
Original Submission: 17 June 2008; Revised Submission: 18 August 2008; Accepted: 22 August 2008
Editor: D. Raoult
Clin Microbiol Infect 2009; 15: 358–363
Corresponding author and reprint requests: H. De Beenhouwer,
Onze Lieve Vrouw Hospital, Moorselbaan 164, 9300 Aalst, Belgium
E-mail: hans.de.beenhouwer@olvz-aalst.be
Introduction
Herpes simplex virus (HSV) infections are very common in
the human population [1]. After primary infection, which
usually occurs during childhood (HSV type 1 or HSV-1) or
adolescence (HSV type 2 or HSV-2), the virus remains latent
for life in the ganglia of sensory neurons, resulting in a large
carrier population among adults. HSV-1 primarily affects the
oropharyngeal mucosa, whereas HSV-2 is mainly involved in
genital infection. Local stimuli (e.g. ultraviolet light and tissue
damage), as well as systemic stimuli (e.g. fever, stress, and
surgery), can lead to virus reactivation and eventually to
overt clinical disease [2].
HSV has increasingly been associated with pulmonary dis-
ease, mostly in immunocompromised hosts. As shown in
recent reports, HSV is frequently present in the upper respi-
ratory tract (URT) of intensive-care unit (ICU) patients [3].
The mucosal damage associated with intubation and mechani-
cal ventilation is a potential trigger for HSV reactivation,
resulting in active secretion in the throat [4–6]. Aspiration
from the URT is said to be the main source of lower respi-
ratory tract (LRT) HSV infections [7,8], but there are also
arguments in favour of the reactivation of the virus in the
lungs or trachea [9]. The detection of HSV in the URT of
ICU patients has recently been associated with a signiﬁcantly
longer ICU stay and increased mortality as compared with
HSV DNA-negative patients [9]. Whether HSV in the LRT
plays an important role in ICU patient outcome is still a
matter of debate. Recent studies suggest an association
between HSV isolation in the LRT and ventilator-associated*Both authors contributed equally.
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pneumonia (VAP) [4,10]. A major obstacle to understanding
the role of HSV in LRT infections is the lack of a clinically
useful diagnostic tool for close and accurate monitoring of
viral activity [3]. A quantitative real-time PCR (Q-PCR) for
the detection of HSV DNA was developed to monitor HSV
kinetics in the LRT samples of patients undergoing long-term
intubation. To evaluate the feasibility of this Q-PCR assay for
monitoring the HSV load in tracheal aspirates (TAs) and
undiluted bronchial aspirates (BAs) of intubated ICU patients,
a prospective observational study was performed in a mixed
medical–surgical ICU of a secondary-care Belgian hospital
(844 beds).
Materials and Methods
Study population
From August 2006 until June 2007, adults (age ‡18 years)
without known immunosuppression admitted to the ICU (24
beds) of Onze Lieve Vrouw Hospital, who were mechanically
ventilated for at least 48 h, were included in a prospective
study. Informed consent was obtained from the relatives at
the time of inclusion. Subjects were mainly surgical patients,
but medical and trauma patients were also included. Immuno-
suppressed patients were excluded, according to the following
criteria: patients who had received radiotherapy, chemother-
apy or immunosuppressive therapy within the preceding
month, or patients who had received high doses of corticos-
teroids (>16 mg/day) within the preceding 3 months; patients
with a leukopenia of <500 polymorphonuclear cells/mm3 of
whole blood; and patients with AIDS or a diagnosed haemato-
logical malignancy. Patients who had received antiviral therapy
before inclusion were also excluded. Upon ICU admission,
patient characteristics, including age, sex, reason for admis-
sion, comorbidities, and disease severity (Simpliﬁed Acute
Physiology Score II), were recorded. Routine laboratory ﬁnd-
ings (C-reactive protein, white blood cell count, creatinine)
and need for dialysis, steroid, antibiotic or antiviral treatment
were recorded during the ICU stay. VAP was deﬁned accord-
ing to the criteria of the American Thoracic Society [11].
Procedures
Serological analysis of anti-HSV-1 and anti-HSV-2 IgG was
carried out at inclusion. TAs or undiluted BAs of ventilated
ICU patients were collected, starting at day 3 of intubation,
and then at least twice a week until extubation. Samples
were processed for HSV monitoring and for routine bacterial
culture.
HSV DNA was detected in TAs and BAs by means of a
Q-PCR targeting the DNA polymerase genes of HSV-1 and
HSV-2. Samples were processed immediately on a daily basis.
Only during weekends samples were stored, at 4C for a
maximum of 72 h. DNA extraction was performed automati-
cally on an NucliSens-EasyMAG platform (bioMe´rieux, Nancy
l’Etoile, France). Q-PCR was performed with the ABI 7000
Sequence Detection System (ABI). The assay was carried out
in a total volume of 25 lL, containing TaqMan universal PCR
master mix without AmpErase UNG (Applied Biosystems,
Foster City, CA, USA), 300 nM forward primer 5¢-CATCAC
CGACCCGGAGAGGG-3¢, 300 nM reverse primer
5¢-GGGCCAGGCGCTTGTTGGTGTA-3¢, 200 nM probe
5¢-FAM-CCGCCGAACTGAGCAGACACCCGCG-TAMRA-3¢
[12], and 5 lL of extracted DNA from the sample.
The Q-PCR protocol was as follows: 10 min of denatur-
ation at 95C, followed by 45 10-s cycles of denaturation at
95C alternating with 1-min annealing and extension at 60C.
A DNA extract of each sample was stored at )80C. Quan-
titation of HSV DNA was performed using a reference curve
obtained with ten-fold dilutions of an HSV standard. The
HSV standard consisted of a plasmid construct containing
the HSV PCR ampliﬁcation product. For reasons
of reproducibility, a cut-off for a positive HSV sample was
arbitrarily set at 103 copies/mL.
Statistical analysis
Data are expressed as median (interquartile range) or
mean ± standard deviation, as appropriate, after exclusion of
outliers detected using Grubb’s test (p <0.05) (GraphPad Soft-
ware Inc., San Diego, CA, USA). Further statistical analysis
was done with MedCalc v9.4.1.0 (Mariakerke, Belgium).
A two-sided test with p <0.05 was judged to be signiﬁcant. An
independent-samples t-test was used for comparison of con-
tinuous variables, and the chi-square test, with Yate’s correc-
tion for continuity if needed, was used for categorical
variables. Continuous data were tested for normality using the
D’Agostino–Pearson test; if they could not be judged to be
normal, normality was obtained by logarithmic transformation.
Results
Analytical performance of the HSV Q-PCR
The HSV Q-PCR was linear in a range of 103–1010 genome
equivalent copies of HSV DNA/mL. The lower limit of detec-
tion (analytical sensitivity) was 102 copies/mL. The speciﬁcity
of the Q-PCR was excellent. No cross-reactivity was
observed with varicella zoster virus, cytomegalovirus,
Epstein–Barr virus, respiratory syncytial virus, human meta-
pneumovirus, adenovirus, Streptococcus pneumoniae, and Hae-
mophilus inﬂuenzae. Minimal inter-run variability (<4%) was
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seen when a low-copy-number positive control (105 copies)
was analysed in ten different runs. The reproducibility of
HSV load per patient was tested for ten different patients by
collecting two samples a few hours apart. Despite the known
variability in sample collection and sample viscosity, a
maximal variation of only 1 log copies/mL (DCt = 3)
between two consecutive samples was found.
Patient results
According to the above-described criteria, 145 non-immuno-
compromised, mechanically ventilated ICU patients were
included in the study (Fig. 1). During analysis, 40 patients had
to be excluded: 36 because of an incomplete sampling proce-
dure during ICU hospitalization, and four because of incom-
plete administrative follow-up. Among the remaining 105
patients, HSV DNA was detected in the LRT of 65 (62%).
Forty-eight of these 65 HSV DNA-positive patients (74%)
were intubated for more than 10 days. Of the 40 HSV
DNA-negative patients, 19 died during HSV monitoring. As it
cannot be excluded that the deceased patients could have
experienced HSV reactivation if they had survived, two sta-
tistical analyses were performed: one general analysis
(Table 1, p1), and one that did not include the 19 HSV-nega-
tive deceased patients (Table 1, p2).
Demographic and clinical characteristics of patients with
and without HSV in the LRT are shown in Table 1. No dif-
ference with respect to age, sex, comorbidities, reason for
40
exclusions
105 study
population 
21 HSV-neg.
survived
19 HSV-
neg. died65 HSV-pos.
42 VAP 7 VAP 
145 inclusions 
9 VAP 
FIG. 1. Flow chart of the study population. HSV, herpes simplex
virus; VAP, ventilator-associated pneumonia.
TABLE 1. Patient characteristics and statistical analysis
All patients
(n = 105)
HSV-positive
(n = 65)
HSV-negative
survived
(n = 21)
HSV-negative
died
(n = 19) p1-value p2-value
Age (years) 67.3 ± 13.1 67.3 ± 12.3 65.7 ± 14.1 69.1 ± 14.9 0.80 0.45
Gender (male) 62 (59) 39 (60) 10 (48) 13 (68) 0.80 0.46
Comorbidities
COPD 7 (7) 4 (6) 1 (5) 2 (11) 0.89 0.76
Cardiological disease 30 (29) 17 (26) 6 (29) 7 (37) 0.63 0.95
Diabetes 11 (10) 9 (14) 2 (10) 0 (0) 0.27 0.89
Community admission 72 (69) 39 (60) 17 (81) 16 (84) 0.03 0.14
Hospital admission 33 (31) 26 (40) 4 (19) 3 (16) 0.03 0.14
Reason for ICU admission
Non-surgical 46 (44) 22 (34) 10 (47) 14 (74) 0.02 0.38
Postsurgical (elective) 46 (44) 32 (49) 9 (43) 5 (26) 0.22 0.80
Postsurgical (non-elective) 13 (12) 11 (17) 2 (10) 0 (0) 0.13 0.64
Antibiotic at admission 14 (13) 12 (18) 2 (10) 0 (0) 0.09 0.53
Pneumonia at admission 13 (12) 8 (12) 5 (24) 0 (0) 0.99 0.54
HSV IgG 91 (94) (n = 97)a 63 (100) (n = 63)b 13 (76) (n = 17)c 15 (88) (n = 17)d 0.003 0.0009
SAPS II 33 (26–46) 32 (25–45) 30 (26–38) 42 (33–53) 0.18 0.99
Steroid treatment in ICU 41 (39) 31 (48) 3 (14) 7 (37) 0.04 0.01
Antibiotic treatment in ICU 101 (96) 64 (98) 20 (95) 17 (89) 0.31 0.98
Renal insufﬁciency 48 (46) 31 (48) 7 (33) 10 (53) 0.75 0.37
Dialysis 21 (20) 13 (20) 4 (19) 4 (21) 0.80 0.83
VAP 58 (55) 42 (65) 7 (33) 9 (47) 0.02 0.02
Shock 64 (61) 40 (62) 11 (52) 13 (68) 0.96 0.63
Sepsis 33 (31) 25 (38) 3 (14) 5 (26) 0.08 0.07
Duration of intubation (days) 11 (7–18) 12 (8–22) 8 (6–10) 8 (5–13) 0.0001 0.008
Length of stay in ICU (days) 14 (9–23) 18 (11–27) 11 (9–14) 10 (6–14) <0.0001 0.002
Length of hospitalization (days) 27 (17–56) 37 (22–61) 24 (21–42) 11 (8–16) <0.0001 0.15
No. of deaths in ICU 42 (40) 23 (35) 0 (0) 19 (100) 0.31 –
COPD, chronic obstructive pulmonary disease; HSV, herpes simplex virus; ICU, intensive-care unit; SAPS II, Simpliﬁed Acute Physiology Score II; VAP, ventilator-associated
pneumonia.
Comparison of HSV-positive patients with total patient group of HSV-negative patients (two-sided signiﬁcance level p1 <0.05) and with HSV-negative patients, excluding the
deceased patients (two-sided signiﬁcance level p2 <0.05). Data are expressed as n (%), as mean ± standard deviation or as median (interquartile range).
aFour patients with no HSV IgG analysis and four patients with doubtful HSV IgG analysis were excluded.
bOne patient with no HSV IgG analysis and one patient with doubtful HSV IgG analysis were excluded.
cTwo patients with no HSV IgG analysis and two patients with doubtful HSV IgG analysis were excluded.
dOne patient with no HSV IgG analysis and one patient with doubtful HSV IgG analysis were excluded.
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ICU admission and Simpliﬁed Acute Physiology Score II was
recorded between the two study populations.
Factors signiﬁcantly associated with HSV positivity in the
LRT were corticosteroid treatment during ICU stay (p1 0.04
and p2 0.01) and a positive anti-HSV IgG serology ﬁnding at
inclusion (p1 0.003 and p2 0.0009). In this study population, a
seroprevalence of 94% (n = 91/97) was found. All patients
with HSV DNA-positive respiratory samples during their stay
at the ICU were seropositive at inclusion (n = 63/63).
HSV-positivity in the LRT was associated with a more com-
plicated course of hospitalization. HSV DNA-positive patients
were intubated for a signiﬁcantly longer period than the HSV
DNA-negative patients (p1 0.0001 and p2 0.008) (median 12
vs. 8 days). Both the length of stay in the ICU and the total
length of hospitalization were signiﬁcantly greater for the HSV
DNA-positive population (both p1 <0.0001). Exclusion of the
deceased patients in the HSV DNA-negative group from the
analyses, however, did not result in a signiﬁcant difference in
the total length of hospitalization (p2 0.15).
VAP developed in 58 (55%) patients, of whom 42 (72%)
had HSV in the LRT (p1 and p2 0.02). However, the in-hospi-
tal mortality (p1 0.31) was comparable between the HSV
DNA-positive group and the HSV DNA-negative group.
Monitoring of the viral load in consecutive samples of
HSV DNA-positive patients revealed a typical kinetic pattern
(Fig. 2). HSV DNA was ﬁrst detected (>103 copies/mL) after
a median of 7 days of intubation (5–11 days) (Fig. 3). This
appearance was followed by an immediate exponential
increase in HSV viral load, by 1.17 (0.95–1.37) log copies/mL
per day, reaching a peak concentration after a median of
12 days of intubation (9.5–15.5 days) (Fig. 4). HSV peak was
deﬁned as the highest HSV viral load found during the entire
monitoring period of one patient. Of all HSV DNA-positive
patients, 78% (n = 51/65) had an HSV viral load peak of at
least 106 copies/mL in the LRT. HSV peak concentrations
were very high in 49% (n = 32/65) of the patients, reaching
between 108 and 1010 copies/mL.
Discussion
In recent years, HSV studies have focused on HSV invasion
of the respiratory tract of immunocompromised or critically
ill patients [3,4,10]. In this study, the population consisted of
intubated ICU patients who were critically ill, a condition
that is accompanied by altered immunity. HSV was detected
with Q-PCR in the LRT of 62% (n = 65/105) of the critically
ill patients. In the bronchial alveolar lavage ﬂuids of a similar
population, Luyt et al. recently found an HSV prevalence of
64% (n = 129/201), using Q-PCR [13]. The lower HSV prev-
alence of 2–50%, as reviewed by Simoons-Smit et al. [3],
might be due to large differences in study design and
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FIG. 2. Typical herpes simplex virus (HSV) kinetic pattern. Monitor-
ing of HSV in the lower respiratory tract of a critically ill patient
shows an exponential HSV increase of 1 log copies/mL per day and a
high HSV peak of 107 copies/mL.
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FIG. 3. First herpes simplex virus (HSV) detection. During monitor-
ing of 21 intubated intensive-care unit patients, HSV became positive
(>3-log copies/ml) after a median of 7 (5–11) intubation days.
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FIG. 4. Herpes simplex virus (HSV) peak. The highest HSV viral load
found by monitoring 21 intubated intensive-care unit patients was
detected after a median of 12 days of intubation (9.5–15.5 days).
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study populations and, most importantly, different sampling
techniques and diagnostic methods, i.e. cell culture and
immunoﬂuorescence assays, which all have much lower sen-
sitivities than Q-PCR.
It is well known that among adults there is a large HSV-1
carrier population [1,13]. As expected, we found, at inclu-
sion, a high seroprevalence of HSV (94%) in our study popu-
lation. Because no primary HSV infection was observed (all
HSV DNA-positive samples analysed by Q-PCR originated
from seropositive patients), HSV reactivation is proposed.
This strengthens the hypothesis that mucosal damage due to
intubation and mechanical ventilation may trigger HSV reacti-
vation. Indeed, in the study of Luyt et al., no primary HSV
infections were found [13].
Whether HSV is a trigger of clinical deterioration is a sub-
ject of ongoing debate. Isolation of HSV from the respiratory
tract has been associated with prolonged ventilation in
immunocompromised and critically ill patients [4,9,13]. Our
study conﬁrmed that there was signiﬁcantly prolonged intu-
bation in HSV DNA-positive patients. Overall, there was not
a signiﬁcant difference in the length of total hospitalization
between both groups, but, nevertheless, the HSV DNA-posi-
tive patients stayed signiﬁcantly longer in the ICU than the
HSV DNA-negative patients. Our results suggest an associa-
tion between HSV isolation and VAP. Luyt et al. reported
slightly more VAP episodes in patients with HSV broncho-
pneumonitis during mechanical ventilation than in patients
without HSV bronchopneumonitis, but the difference was
not signiﬁcant [13].
Q-PCR is a fast and reliable method for the quantitative
detection of HSV. We chose a quantitative method of HSV
detection, rather than cell culture, in order to be able to
study the kinetics of HSV infection during intubation.
Because of the excellent sensitivity of Q-PCR, very low HSV
concentrations can be detected very quickly as compared
with cell culture. TAs and BAs were sampled rather than
bronchial alveolar lavage ﬂuid, because these samples are
readily available and are obtained with less stress for the
patient, and because no dilution factor has to be taken into
account. The Q-PCR results showed that TAs and BAs are
valuable samples for the detection of low as well as high
HSV viral loads. Thanks to the excellent reproducibility of
the Q-PCR for the quantitative measurement of HSV, moni-
toring of HSV viral loads in consecutive samples from a
patient has become feasible. In most patients intubated for
‡10 days, monitoring showed very homogeneous curves,
with almost symmetrical increases and reductions in HSV.
We observed a typical pattern of HSV kinetics in the LRT of
critically ill patients. In 75% of monitored patients, HSV
emerged in TAs and BAs within 11 days of mechanical venti-
lation. An exponential increase in HSV viral load takes place
with a median of about 1 log copies/mL/day, with an HSV
peak being rapidly attained. HSV peak concentrations were
very high in half of the patients, varying between 108 and
1010 copies/mL. It is difﬁcult to imagine that these extremely
high HSV concentrations are not clinically relevant. Viral
loads of 108 copies/mL in the LRT are comparable to the
virus concentrations typically found in buccal herpes vesicles.
One might assume that such high HSV concentrations result
in heavy tissue damage in the LRT. In patients with HSV
bronchopneumonitis, Luyt et al. found a signiﬁcant associa-
tion with oral–labial lesions, HSV in the throat, and bronchial
lesions with mucosal erythema and/or a few superﬁcial ulcer-
ations [13]. The same author suggested that lung involve-
ment of HSV causing bronchopneumonitis was related to the
viral load. A quantitative measurement of the HSV viral load
could allow its use as a surrogate for cytological examination
to diagnose a clinically relevant HSV infection. This empha-
sizes the reason for the development of a quantitative HSV
Q-PCR. The viral load can give an idea of the extent of the
viral reactivation and thus of the clinical impact [14]. Indeed,
three patients were found with low viral loads, of 103–
104 copies/mL, whose successive samples became negative.
This suggests that the immunological response is very impor-
tant for the management of HSV reactivation. In this study,
30 (46%) of the HSV-positive patients received acyclovir, on
the basis of the suspicion of a possible association of high
HSV viral load and clinical deterioration.
The treatment was started at the physician’s discretion.
No signiﬁcant difference in patient outcome or decrease in
HSV viral load was found between the patients with or with-
out acyclovir treatment. This study was not intended to ana-
lyse the outcome of HSV-positive patients in relation to
antiviral treatment; therefore, no assumptions about the
effect of acyclovir can be made.
The primary aim of the present study was to monitor the
course of HSV kinetics in the LRT of critically ill patients.
No strong conclusions can be drawn concerning the impact
of HSV on morbidity and mortality, because of two substan-
tial shortcomings. First, the cause of death of the HSV-posi-
tive patients was not recorded, but the unblinded acyclovir
administration may have a major inﬂuence on the outcome.
Furthermore, we can only assume that the death of the 19
HSV DNA-negative patients was not due to HSV, because
these patients did not show virus reactivation before they
died. The second shortcoming is that, after exclusion of indi-
viduals from the patient groups, the smaller study population
inevitably allowed less robust conclusions. Forty patients
were excluded from statistical analysis because of incomplete
sampling procedures during ICU hospitalization or incom-
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plete administrative follow-up. An additional 19 HSV-negative
patients died during HSV monitoring. If these patients were
still alive, some would probably become HSV-positive. Thus,
keeping them in the study population of HSV-negative
patients may bias the statistical results. For this reason, a sta-
tistical analysis excluding the 19 HSV-negative deceased
patients was also performed. Although the most important
ﬁndings could be conﬁrmed in this analysis, the results were
less signiﬁcant. Larger studies will therefore be needed to
conﬁrm our ﬁndings.
In conclusion, Q-PCR is a reliable technique for rapid detec-
tion of HSV in respiratory tract samples. In this prospective
study, the frequency of HSV in the LRT of critically ill patients
under mechanical ventilation was found to be high (62%). The
study showed that isolation of HSV was signiﬁcantly associated
with prolonged mechanical ventilation and longer ICU stay.
Monitoring of HSV demonstrated typical HSV kinetics, with an
exponential HSV increase of 1 log/mL/day and, often, very high
HSV peaks. Further studies are needed that focus on the effect
of antiviral therapy vs. placebo to analyse the inﬂuence on the
outcome of HSV-positive ICU patients, on the incidence of
VAP, and on antibiotic consumption.
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